▽tositumomab - PubMed - NCBI ●01/09 16:44 Tositumomab.[No authors listed] [No authors listed] 2020 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and
▽NCCN Clinical Practice Guidelines in Oncology ●01/09 16:31 Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and GastricLung Cancer Screening Prostate Cancer Early DetectionVersion: 3.2024Version: 3.2024Version: 2.2025
▽U S Food and Drug Administration Home Page ●01/09 14:45 CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024The 2024 New Drug Therapy Approvals report features drug approvals that CDER considers likely to have a significant impact on public health.Obesity and Overweight: Developing Drugs and Biological Products for Weight ReductionDrugs
▽blinatumomab - PubMed - NCBI ●01/09 13:40 2024 1642025 71,054 resultsBlinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.Goebeler ME, Bargou R. Goebeler ME, et al. Leuk Lymphoma. 2016 May;57(5):1021-32. doi: 10.3109/10428194.2016.1161185. Epub 2016 Apr 6. Leuk Lymphoma. 2016. PMID: 27050240 Review.Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispec
